Suprofen, a potent antagonist of sodium urate crystal-induced arthritis in dogs.
A standardized sodium urate-induced arthritis test in dogs is described in detail. A microcrystalline suspension of 20 mg/ml in 0.9% NaCl was injected into one of the stifle joints in a volume of 0.5 ml and motor impairment of the dogs was scored every 30 min over a period of 8 h. A direct quantitative comparison was made of the anti-arthritic activity of acetyl-salicylic acid, phenylbutazone, indometacin and alpha-methyl-4-(2-thienylcarbonyl)benzeneacetic acid (suprofen). All compounds were given by oral gavage immediately after the sodium urate injection. Among the compounds studied suprofen was the most potent antagonist of sodium urate-induced arthritis in dogs. Comparing the ED50 values suprofen was about 4 times as potent as indometacin, 9 times as potent as phenylbutazone and 60 times as potent as acetyl-salicylic acid.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001168:Arthritis / Q000139:chemically induced / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005260:Female; D007213:Indomethacin / Q000627:therapeutic use; D007719:Knee Joint; D008297:Male; D010653:Phenylbutazone / Q000627:therapeutic use; D010666:Phenylpropionates / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*; D013997:Time Factors; D014527:Uric Acid
D000893:Anti-Inflammatory Agents; D010666:Phenylpropionates; D013876:Thiophenes; D014527:Uric Acid; D010653:Phenylbutazone; D001241:Aspirin; D007213:Indomethacin